Business
Pfizer ends COVID-19 vaccine trial with 95 per cent efficacy – Sydney Morning Herald
Effectiveness of the vaccine was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunisation could…
The better-than-expected data from the two vaccines, both developed with new technology known as messenger RNA (mRNA), have raised hopes for an end to a resurgent pandemic that has killed more than 1.3 million people globally and wreaked havoc upon economies and daily life.
However, while some groups such as healthcare workers will be prioritised in the United States for vaccinations this year, it will be months before large-scale rollouts begin.
Pfizer said on Wednesday there had been 170 cases…
-
General21 hours agoWA government rolls out suite of housing assistance ahead of state budget
-
Noosa News22 hours agoPolice investigate fire at Borrodell Estate winery restaurant near Orange
-
Business24 hours agoHow much upside does Macquarie see for Collins Foods shares?
-
Business23 hours agoLeading brokers name 3 ASX shares to buy today 16 June 2025